Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Public ClinicalTrials.gov record NCT05786924. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies
Study identification
- NCT ID
- NCT05786924
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 554 participants
Conditions and interventions
Conditions
- Acquired Resistance to KRAS G12C Inhibitor
- BRAF
- BRAF Gene Mutation
- BRAF Mutation-Related Tumors
- BRAF V600 Mutation
- BRAF V600E
- Brain Metastases
- Colorectal Cancer
- Colorectal Carcinoma
- Histiocytic Neoplasm
- Histiocytosis
- KRAS G12A
- KRAS G12D
- KRAS G12F
- KRAS G12R
- KRAS G12V
- KRAS G13C
- KRAS G13D
- KRAS Mutation-Related Tumors
- Metastatic Lung Cancer
- Metastatic Lung Non-Small Cell Carcinoma
- NRAS Gene Mutation
- NSCLC
- Non-small Cell Lung Cancer
- Recurrent Histiocytic and Dendritic Cell Neoplasm
- Recurrent Lung Cancer
- Recurrent Lung Non-Small Cell Carcinoma
- Recurrent NSCLC
- Solid Carcinoma
- Solid Tumor
- Thyroid Cancer
- Thyroid Carcinoma
Interventions
- Cetuximab Drug
- FOLFIRI Drug
- FOLFOX6/FOLFOX7 Drug
- Gemcitabine Drug
- Nab-paclitaxel Drug
- Panitumumab Drug
- S241656 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 17, 2023
- Primary completion
- May 31, 2028
- Completion
- May 31, 2028
- Last update posted
- Apr 20, 2026
2023 – 2028
United States locations
- U.S. sites
- 10
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner Health- MD Anderson Cancer Center | Gilbert | Arizona | 85234 | Recruiting |
| University of Colorado - Aurora Cancer Center | Aurora | Colorado | 80045 | Not yet recruiting |
| Georgetown University Lombardi Cancer Center | Washington D.C. | District of Columbia | 20007 | Not yet recruiting |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | Recruiting |
| South Texas Accelerated Research Therapeutics (START) Midwest | Grand Rapids | Michigan | 49546 | Recruiting |
| Masonic Cancer Center University of Minnesota | Minneapolis | Minnesota | 55455 | Recruiting |
| Washington University | St Louis | Missouri | 63130 | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Recruiting |
| NEXT Virginia | Fairfax | Virginia | 22031 | Recruiting |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
Recently updated Colorectal Cancer trials
Other public records listing Colorectal Cancer. Sorted by last update posted; newest first. Not a recommendation.
- NCT07796334: Colon Health Champion Program Not yet recruiting
- NCT07071961: Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial] Recruiting
- NCT07781852: Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer Not yet recruiting
- NCT07781774: Improving Colorectal Cancer Screening Uptake Through Education and Stool-Based Testing Outreach Not yet recruiting
- NCT07759921: Novel Couple-Based Mindfulness Intervention for Metastatic Colorectal Cancer Not yet recruiting
- NCT07738939: IKS04 Regimen in Advanced Solid Tumors That Express CA242 Not yet recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05786924, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 20, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05786924 live on ClinicalTrials.gov.